Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

334
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
334
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

256
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
256
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

257
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
257
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

416
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
416
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

291
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
291
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

257
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
257

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An interventional pilot study protocol on the effect of extra virgin olive oil on women with preeclampsia risk.

Annals of translational medicine·2026
Same author

A prediction model for childhood obesity risk based on maternal thyroid status and related parameters using machine learning: a mother-newborn-offspring study in a mild-to-moderate iodine deficiency area.

International journal of obesity (2005)·2025
Same author

Stillbirth Discourse on Instagram and X (Formerly Twitter): Content Analysis.

JMIR infodemiology·2025
Same author

[THYROTOXICOSIS WITH PROLONGED CARDIAC EFFECT DUE TO EXCESS LIOTHYRONINE CONSUMPTION 'OVER THE COUNTER': A CASE REPORT AND RECOMMENDATIONS FOR POLICY MAKERS].

Harefuah·2025
Same author

The War in Gaza and Barriers to Inflammatory Bowel Disease Care.

JGH open : an open access journal of gastroenterology and hepatology·2025
Same author

Fetoplacental unit involvement in uric acid production in women with severe preeclampsia: a prospective case control pilot study.

The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians·2024

Related Experiment Video

Updated: Sep 10, 2025

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

348

Semaglutide Overdose in a Diabetic Patient: Suicidal Behavior and Multiorgan Failure.

Doron Zamir1,2, Yaniv S Ovadia1,3, Ofer Ben-Bassat4

  • 1Department of Internal Medicine D, Barzilai University Medical Center, Ashkelon, Israel.

The American Journal of Case Reports
|August 24, 2025
PubMed
Summary

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), like Semaglutide, are increasingly used. A case report details a patient experiencing severe outcomes after a Semaglutide overdose, suggesting a need for mental health screening.

More Related Videos

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.0K
Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

340

Related Experiment Videos

Last Updated: Sep 10, 2025

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

348
Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.0K
Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

340

Area of Science:

  • Endocrinology
  • Pharmacology
  • Gastroenterology

Background:

  • Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have seen increased use for diabetes and weight management.
  • Semaglutide prescriptions have risen for both approved and unapproved indications.
  • A potential association between GLP-1 RAs and suicidal behavior has been suggested.

Purpose of the Study:

  • To report a rare case of suicide-related behavior and adverse outcomes following a self-administered Semaglutide overdose.
  • To highlight potential risks associated with Semaglutide use and overdose.

Main Methods:

  • Case report of a 67-year-old male patient with diabetes and overweight.
  • Detailed clinical presentation, treatment, and patient history regarding Semaglutide use.
  • Analysis of the patient's self-injected overdose and its potential link to suicidal behavior.

Main Results:

  • The patient presented with multiorgan failure, hypoglycemia, cholestatic liver dysfunction, and duodenal ulcers after self-injecting an overdose of Semaglutide.
  • Clinical status improved with treatment, including healing of duodenal ulcers.
  • The overdose was considered potentially suicidal behavior given the patient's history and reported dysphoria.

Conclusions:

  • Patients prescribed GLP-1 RAs, such as Semaglutide, should be screened for mental health conditions.
  • Multiorgan failure should be considered in Semaglutide-treated patients experiencing acute illness.
  • This case underscores the importance of monitoring for adverse psychiatric effects and overdose in patients using GLP-1 RAs.